1,272 results on '"Palandri, Francesca"'
Search Results
2. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)
3. Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes
4. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
5. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
6. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
7. Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
8. Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
9. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial
10. Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib
11. Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
12. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
13. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera
14. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT
15. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.
16. VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
17. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
18. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
19. Second versus first wave of COVID-19 in patients with MPN
20. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
21. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
22. Breakthrough infections in MPN-COVID vaccinated patients
23. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet
24. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
25. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
26. Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study.
27. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives.
28. Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial.
29. Spinal Cord Compression from Widespread Extramedullary Hematopoiesis in Polycythemia Vera
30. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
31. Is there a gender effect in polycythemia vera?
32. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
33. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
34. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms
35. Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease
36. How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
37. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
38. The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
39. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
40. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
41. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
42. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
43. POSTER: MPN-093 Impact of Transfusion Burden on Health-Related Quality of Life and Functioning in Patients With Myelofibrosis: Post Hoc Analysis of SIMPLIFY-1 and -2
44. MPN-548 Phase I/II Study of the Activin Receptor-Like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis
45. MPN-193 Incidence of Blast Phase in Myelofibrosis According to Anemia Severity
46. POSTER: MPN-559 Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study
47. POSTER: MPN-092 Indirect Treatment Comparisons of Momelotinib vs Pacritinib Safety and Anemia Outcomes in Patients With Myelofibrosis
48. MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion
49. POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion
50. MPN-559 Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.